The FDA has ordered manufacturers of all GLP-1 receptor agonist medications to add information about a rare eye condition, non-arteritic anterior ischemic optic neuropathy (NAION), to the 'Warnings and Precautions' section of their labeling.

The class-wide directive covers a dozen pill-based and injectable drugs, including Novo Nordisk's Ozempic, Wegovy and Rybelsus, Eli Lilly's Mounjaro and Zepbound, and Sanofi's Soliqua.

NAION occurs when blood flow to the front of the optic nerve is suddenly reduced, causing acute, painless vision loss in one eye that can become permanent. The agency said NAION cases have been reported across every currently marketed GLP-1 product.

Although the FDA concluded only that there is a 'potential increased risk' and did not establish causation, the regulator decided further assessment was warranted.

The move also aligns with earlier international signals: CNN reports that last year the European Medicines Agency's safety committee said NAION may affect up to 1 in 10,000 people taking semaglutide for at least one year, and that four Danish patients who suffered vision loss were granted compensation.

The FDA's safety review spanned clinical trial registries, animal data and post-marketing reports. The agency analyzed 126 clinical trials involving more than 134,000 patients and identified 15 probable NAION cases, 10 among GLP-1 patients and 5 among those on placebo.

Fox Business reports the meta-analysis found roughly six cases per 100,000 patients taking GLP-1 drugs over a one-year period, compared with fewer than four cases among patients on placebo or other glucose-lowering medications — about a 68% higher rate.

The FDA cautioned the findings do not establish a causal link, noting that diabetes, high blood pressure and sleep apnea are risk factors for NAION that also overlap heavily with the GLP-1 patient population.

The absolute numbers remain small. Of the roughly 78,000 patients included in the studies reviewed by the FDA, Fox Business reports just 10 experienced vision loss, approximately 0.01% of participants.

NAION is most common in adults over 50, who often experience sudden, painless vision loss in one eye upon waking, with symptoms including blurred vision, distorted color perception and blind spots.

There is no proven treatment to reverse the damage, though research cited by Fox Business found about 43% of patients with significant vision impairment see some spontaneous improvement, even as visual field defects often persist.

Both major manufacturers stressed that the labeling change does not prove causation. Novo Nordisk said it 'continues to believe the data do not establish a cause-and-effect relationship' and remains confident in the benefit-risk profile of its GLP-1 medicines.

Eli Lilly said the FDA communication applies to all medicines with GLP-1 RA activity and does not reference findings specific to its medicines, adding it would respond to the agency promptly.

CNN reports Citi analyst Geoff Meacham expects the action may temporarily raise patient and investor concern, but that the rarity of NAION and the substantial weight, glycemic, cardiovascular, renal and sleep apnea benefits should preserve a favorable benefit-risk profile.

Physicians quoted in the coverage advise patients not to stop their prescribed GLP-1 regimens abruptly without consulting their healthcare providers, but urge anyone experiencing sudden changes in eyesight, blurred vision or partial vision loss to seek immediate evaluation from an ophthalmologist.

The NAION warning joins existing safety flags: Clarin reports several leading GLP-1 therapies already carry the FDA's most prominent boxed warning about a potential risk of thyroid C-cell tumors, which stems from rodent studies and remains unproven in humans.

The labeling update gives prescribers a new consideration while leaving the commercial momentum of the blockbuster drug class, by most analyst expectations, largely intact.